CalbaTech Announces UCIrvine Cooperative Research Program Hits Technical Milestone in Development of Respiratory Pathogen Chip

13.04.2004

Irvine. CalbaTech, Inc., an emerging Life Sciences company concentrating on providing products and platforms to the research market, for biotech and pharmaceutical companies, and academic institutions, today announced a first, significant technical milestone in cooperative effort with the University of California, Irvine, concerning the development of a respiratory pathogen chip.

The collaborative research and development project has developed the first prototype of a DNA array which can detect the presence of a range of commonly occurring respiratory pathogens including influenza viruses, rhinoviruses (common cold viruses) coronaviruses (including the SARS virus), RSV, Chlamydia pneumoniae, and other commonly occurring pathogens. Once fully optimized, the panel will be made available for pathogen detection in clinical pathology laboratories, disease surveillance and research.

"This DNA array project perfectly complements CalbaTech's other development programs on DNA isolation, DNA detection, and associated data handling currently ongoing within the Company's research and development efforts," said James DeOlden, CEO.

CalbaTech, Inc. is an emerging life sciences company concentrating on providing products and platforms to the research market, for biotech and pharmaceutical companies, and academic institutions. CalbaTech is focused on acquiring, incubating and developing early stage life science companies that are developing next generation products and technologies, both in the United States and in the United Kingdom. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that will contribute breakthrough innovation in areas of biological discovery.

Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.

https://www.bionity.com/de/news/36668/calbatech-announces-ucirvine-cooperative-research-program-hits-technical-milestone-in-development-of-respiratory-pathogen-chip.html